Latest Press Releases

WeightWatchers Unveils Next-Gen Program With AI-Powered App Features

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced the launch of its innovative next-gen program, introducing advanced features designed to make weight management ...

CEPI and Accumulus Synergy Team up to Enhance Information Equity and Accelerate Access to Vaccines

OSLO, Norway and BURLINGAME, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy’s innovative cloud-based data-sharing platform could accelerate access to vaccines and other health technologies by enabling multi-country regulatory ...

RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases

BENGALURU, India, Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. This funding will ...

AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer

AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, ...

TECH CULTURES: Politecnico di Torino Opens a call for Expression of Interest for Guest curators in the Biennale Tecnologia 2026 Festival

TURIN, Italy, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Technology has assumed an increasingly decisive role in social development and in all areas of human life, from education to work, from the environment to health. In order to investigate the ...

AWHP Supports USPSTF's Updated Draft Cervical Cancer Guidelines

PR Newswire WASHINGTON, Dec. 10, 2024 "A" rating of co-testing is critical to ensure patient-provider choice and access WASHINGTON, Dec. 10, 2024 /PRNewswire/ -- Today, the U.S. Preventive Services Task Force (Task Force) issued new ...

MemorialCare Hospitals Named 2025 High Performing Hospital for Maternity Care by "U.S. News & World Report"

PR Newswire FOUNTAIN VALLEY, Calif., Dec. 10, 2024 FOUNTAIN VALLEY, Calif., Dec. 10, 2024 /PRNewswire/ -- U.S. News & World Report, the global authority in hospital rankings and consumer advice, has named MemorialCare's Miller Children's & ...

Genotyping Market Size Estimated to be Worth USD 154.35 Billion by 2031, at 22.5% CAGR: The Insight Partners

PR Newswire NEW YORK, Dec. 10, 2024 The genotyping market in North America is expected to grow from US$ 11,734.10 million in 2022 to US$ 37,599.28 million by 2028. It is estimated to grow at a CAGR of 21.4% from 2022 to 2028. NEW YORK, ...

Peptide Synthesis Market to Reach USD 1.12 Billion by 2031, Driven by Advancements in Drug Development and Rising Demand for Therapeutics: - Market Research Intellect

PR Newswire LEWES, Del., Dec. 10, 2024 The peptide synthesis market is witnessing robust growth, fueled by increasing demand for peptide-based drugs in treating chronic diseases like cancer and diabetes. Advancements in synthesis ...

Minimal Residual Disease Market to Hit USD 2.55 Billion by 2029 with 12.2% CAGR | MarketsandMarkets™

PR Newswire DELRAY BEACH, Fla., Dec. 10, 2024 DELRAY BEACH, Fla., Dec. 10, 2024 /PRNewswire/ -- The global Minimal Residual Disease market is expected to grow to USD 2.55 Billion by 2029, up from USD 1.43 Billion in 2024, at a CAGR of 12.2% ...

Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma

PR Newswire SAN DIEGO, Dec. 10, 2024 Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular ...

Genetic Profile Linked with High-Altitude Andean Population Correlates with Better Response to Treatment for Myeloproliferative Neoplasms

PR Newswire SAN DIEGO, Dec. 10, 2024 Variants could serve as biomarker to inform prognosis or guide treatment decisions LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in ...

Stem Cell Transplant Offers No Additional Benefit for Patients with Mantle Cell Lymphoma in Deep Remission

PR Newswire SAN DIEGO, Dec. 10, 2024 Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in ...

Undergoing Stem Cell Transplant for Sickle Cell Disease in Childhood Improves Quality of Life a Decade Later

PR Newswire SAN DIEGO, Dec. 10, 2024 Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 ...

Neuropathy Action Foundation Launches White Paper on the Promise and Potential Hazards of Artificial Intelligence (AI) for Neuropathy

PR Newswire SANTA ANA, Calif., Dec. 10, 2024 NAF calls for increased awareness and advocacy around use of AI to prevent potential abuses SANTA ANA, Calif., Dec. 10, 2024 /PRNewswire/ -- The Neuropathy Action Foundation (NAF), a ...

?2024 ASH?TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies

PR Newswire NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical ...

UMass Memorial Health Integrates AEYE Health's AEYE-DS Autonomous AI Screening for Diabetic Eye Care into EMR System

PR Newswire NEW YORK, Dec. 10, 2024 In Memory of Dr. James Ledwith NEW YORK, Dec. 10, 2024 /PRNewswire/ -- AEYE Health , the leader in artificial intelligence-based diagnostics for retinal imaging, and UMass Memorial Health (UMMH), the ...

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

PR Newswire EAST HANOVER, N.J., Dec. 10, 2024 EAST HANOVER, N.J., Dec. 10, 2024 /PRNewswire/ -- Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the ...

Highly bioavailable transdermal gel from Vascarta may offer a safe and effective new way to treat sickle cell disease - presentation at American Society of Hematology Conference

PR Newswire SAN DIEGO, Dec. 10, 2024 SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Vascarta Inc. ("Vascarta") reported new research findings at the 66th Annual American Society of Hematology meeting in San Diego showing that their novel ...

Alveo Technologies and Fraunhofer Partner to Develop First-of-its-Kind Rapid, Molecular Feline Respiratory Panel Diagnostic

PR Newswire ALAMEDA, Calif., Dec. 10, 2024 The two companies will develop a test for feline influenza, calicivirus and herpes virus-1 that provides accurate results in minutes at point of need ALAMEDA, Calif., Dec. 10, 2024 /PRNewswire/ ...

The START Center for Cancer Research Expands its Capabilities to Support Early-Phase Hematological Cancer Trials

PR Newswire SAN ANTONIO, Dec. 10, 2024 Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies SAN ANTONIO, Dec. 10, 2024 /PRNewswire/ -- The ...

Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications

PR Newswire FREDERICK, Md., Dec. 10, 2024 FREDERICK, Md., Dec. 10, 2024 /PRNewswire/ -- Theradaptive, a privately held, clinical stage biologics company developing protein therapeutics for spine, orthopedics, soft tissue repair, and targeted ...

Aura Launches Clinical Study to Assess the Link Between Technology Use and the Mental Wellness of Our Children

PR Newswire BOSTON, Dec. 10, 2024 Study aims to measure impact of technology usage on youth mental health outcomes BOSTON, Dec. 10, 2024 /PRNewswire/ -- Aura, the leading all-in-one online safety solution for individuals and families, is ...

Vital Data Technology Announces Agreement with Mid-State Health Network to Provide Predictive Models for Mental Health and Substance Use Disorders

PR Newswire NEWPORT BEACH, Calif., Dec. 10, 2024 NEWPORT BEACH, Calif., Dec. 10, 2024 /PRNewswire/ -- Vital Data Technology, a leading provider of AI-driven health data analytics and medical management solutions for health plans, announced ...

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

PR Newswire ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and ...

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

PR Newswire ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and ...

ConTIPI Medical & EVERSANA Announce U.S. Commercial Launch of Non-Surgical Medical Device ProVate for Women With Pelvic Organ Prolapse

PR Newswire CHICAGO, Dec. 10, 2024 CHICAGO, Dec. 10, 2024 /PRNewswire/ -- ConTIPI Medical, an innovator in providing non-surgical and disposable solutions for women with various pelvic floor dysfunctions, and EVERSANA, a leading provider of ...

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

PR Newswire GAITHERSBURG, Md., Dec. 10, 2024 GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first ...

Kira Pharmaceuticals Presents Updated Data of Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH) at American Society of Hematology (ASH) 2024 Demonstrating Long-Term Safety and Efficacy

PR Newswire CAMBRIDGE, Mass., Dec. 10, 2024 CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today ...

Curis Announces Additional Data from TakeAim Leukemia Study

PR Newswire LEXINGTON, Mass., Dec. 10, 2024 LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small ...

Inspira™ Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions

PR Newswire RA'ANANA, Israel, Dec. 10, 2024 RA'ANANA, Israel, Dec. 10, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology ...

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

PR Newswire HENDERSON, Nev., Dec. 10, 2024 HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which ...

Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

PR Newswire LEHI, Utah, Dec. 10, 2024 LEHI, Utah, Dec. 10, 2024 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today ...

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

PR Newswire ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and ...

Endo Launches Doxycycline for Injection, USP

PR Newswire MALVERN, Pa., Dec. 10, 2024 MALVERN, Pa., Dec. 10, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has begun shipping doxycycline for injection, USP 100 mg/vial, an AP-rated version of DOXY 100™. ...

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

PR Newswire ANNAPOLIS, Md., Dec. 10, 2024 Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing ...

Introducing the Gianna Lullume Smart Infant Sleep Device: A Revolutionary Solution for Infant Sleep Now on Kickstarter

PR Newswire HONG KONG, Dec. 10, 2024 HONG KONG, Dec. 10, 2024 /PRNewswire/ -- The Gianna Lullume Smart Infant Sleep Device, an innovative product developed by Kerchan Group, has officially launched on Kickstarter. This innovative sleep aid ...

Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis

PR Newswire SYDNEY, Dec. 10, 2024 SYDNEY, Dec. 10, 2024 /PRNewswire/ -- Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating ...

PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series

PR Newswire MONTVALE, N.J., Dec. 10, 2024 MONTVALE, N.J., Dec. 10, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series—PENTAX ...

From 2020 to 2023, Cancer Treatment Rates Increased 11.7 Percent in Patients Aged 18 to 29, According to FAIR Health Study

PR Newswire NEW YORK, Dec. 10, 2024 The Five Most Common Types of Cancer in Adults Aged 18 to 49 in 2023 Were Skin, Breast, Thyroid and Other Endocrine Glands, Digestive Organs and Female Genital Organs NEW YORK, Dec. 10, 2024 ...

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and ...

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

PR Newswire EDINBURGH, Scotland and LONDON, Dec. 10, 2024 EDINBURGH, Scotland and LONDON, Dec. 10, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on ...

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

PR Newswire CAMBRIDGE, Mass., Dec. 9, 2024 CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody ...

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

PR Newswire SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the ...

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH

PR Newswire BUFFALO, N.Y., Dec. 9, 2024 About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that ...

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

PR Newswire SAN DIEGO, Dec. 9, 2024 89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently ...

Latest Press Releases

Premium Press Releases »

Press Releases »

Medindia Newsletters

Latest Press Releases

Follow Us On :